Business & Industry

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, in a move that significantly expands its presence in immunology and rare diseases. The Biogen to Acquire Apellis deal stands among the company’s largest transactions to date,...

The US pharma tariffs policy has been formalised through an executive order signed by Donald Trump, introducing tariffs of up to 100% on imported branded medicines. The measure targets pharmaceutical companies that have not entered into drug pricing agreements...

Britain has finalised a UK-US pharma trade deal, securing tariff-free access for UK-made medicines to the United States while committing to higher domestic spending and pricing adjustments for new drugs. The agreement, part of a broader bilateral trade framework...

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic...

Johnson & Johnson has received a key regulatory endorsement in Europe, marking a significant shift in how oncology treatments can be administered. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has approved a...

Japanese pharmaceutical company Otsuka has moved to deepen its presence in the emerging neuroplastogen space through an agreement to acquire Transcend Therapeutics, bringing with it a promising MDMA-based candidate targeting post-traumatic stress disorder (PTSD) and related psychiatric conditions. The...

Novartis has entered into an agreement to acquire biotech firm Excellergy, a move that will bring a next-generation anti-immunoglobulin e (IgE) programme into its pipeline. Excellergy acquisition is structured at up to $2bn in upfront and milestone payments and...